Holt-Oram syndrome (HOS) is a genetic developmental disorder that associates upper limb abnormalities, especially of the radial ray, with congenital heart malformations and/or cardiac conduction abnormalities. It is mainly caused by pathogenic variants in the TBX5 gene and follows an autosomal dominant inheritance pattern. The alteration of this transcription factor interferes with embryonic programs essential for the coordinated formation of the heart, arms, and hands.
Holt-Oram Syndrome
The TBX5 gene (T-Box Transcription Factor 5) encodes a transcription factor that binds to DNA and regulates the expression of other genes involved in embryonic development. Its function is particularly relevant in the formation of the upper limbs, specifically the radial axis that gives rise to the thumb, radius, and carpal structures, and in the development of the cardiac septa and the heart's electrical conduction system. Pathogenic variants in TBX5 reduce the amount or function of the TBX5 protein, producing a haploinsufficiency defect or an alteration in its ability to bind to DNA and activate target genes. As a consequence, congenital malformations of the upper limbs and structural cardiac defects, especially atrial or ventricular septal defects, along with a risk of conduction disorders, occur. The disease is inherited in an autosomal dominant manner; each offspring of an affected individual has a 50% chance of inheriting the variant. Clinical expressivity is highly variable, even within the same family, and many cases appear de novo. Its incidence is estimated at around 1 in 100,000 live births.
Symptoms
SHO is present from birth, although manifestations can be mild and go unnoticed initially. Upper limb anomalies affect the radial ray and can range from thenar eminence hypoplasia, hypoplastic, triphalangeal or absent thumb, to radial hypoplasia or absence and significant forearm shortening. The alterations are usually bilateral and asymmetrical. Cardiac involvement can include septal defects, complex cardiac malformations, and conduction disorders such as sinus bradycardia or atrioventricular block, which can progress unpredictably. Cognitive development is generally not affected.
Disease management
The management of Holt-Oram syndrome is multidisciplinary and focuses on early detection and treatment of cardiac and functional complications. Cardiologic evaluation with electrocardiogram and echocardiogram is recommended at diagnosis, as well as periodic follow-up to identify structural defects, arrhythmias, or conduction abnormalities; some patients may require cardiac surgery, pharmacologic treatment, or pacemaker implantation. Upper limb anomalies are managed with rehabilitation, occupational therapy, orthopedic surgery, or prostheses when necessary to improve function. Genetic counseling is important to assess family risk, study at-risk family members, and offer prenatal or preimplantation diagnostic options if the causal variant is known.
Genes analyzed
Bibliography
Vanlerberghe C, Petit F. Holt-Oram Syndrome. 2004 Jul 20 [updated 2025 Jul 31]. In: Adam MP, Bick S, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2025.
Krauser AF, Ponnarasu S, Schury MP. Holt-Oram Syndrome. 2023 Aug 14. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–.
Skwarek-Dziekanowska A, Wójtowicz-Ściślak A, Sobieszek G. Holt-Oram syndrome. Eur Rev Med Pharmacol Sci. 2024 Jan;28(1):336-341.
